Shares of Olympus Co. (OTCMKTS:OCPNY – Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $18.00 and traded as low as $18.00. Olympus shares last traded at $18.00, with a volume of 400 shares.
Olympus Stock Down 1.4%
The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.48 and a current ratio of 1.99. The firm has a fifty day simple moving average of $18.00 and a 200-day simple moving average of $18.00. The firm has a market cap of $23.15 billion, a price-to-earnings ratio of 21.95, a P/E/G ratio of 1.07 and a beta of 0.70.
Olympus Company Profile
Olympus Corporation is a Tokyo-headquartered manufacturer specializing in medical and scientific imaging, precision optics and related equipment. The company’s medical systems business is focused on endoscopic technologies and therapeutic devices used in minimally invasive diagnosis and treatment, supplying hospitals and clinical facilities with endoscopes, visualization platforms and accessories. In addition to healthcare, Olympus serves scientific and industrial customers with microscopes, imaging systems, non-destructive testing equipment and precision measurement tools used in research, manufacturing and quality control.
In recent years the company completed a strategic refocus on healthcare and scientific solutions, divesting its consumer camera business in 2020 to concentrate resources on medical device development, services and life-science applications.
Featured Stories
- Five stocks we like better than Olympus
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- New Banking Law #1582 Could Unlock $21 Trillion for Americans
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.
